Study group | Gestational age [weeks] |
||
---|---|---|---|
25-28 29-32 | 33-36 | 37-41 | |
Newborns [ |
9/12.33 25/34.25 | 28/38.35 | 11/15.07 |
Gestational age [weeks] |
Dose [mg/kg] |
Dosing range [hours] |
---|---|---|
<29* | 5 | 48 |
30 do 33 | 4.5 | 48 |
34 do 37 | 4 | 36 |
>38 | 4 | 24 |
Reference source |
Compared therapeutic range [mg/L] |
Percentage of newborns reaching the therapeutic range |
---|---|---|
Hospital therapeutic range [ |
1-2 | 26.32% |
Neofax [ |
0.5-1 | 32.89% |
Begg [ |
<1 | 80.92% |
van Maarseveen [ |
<0.5 | 38.35% |
Reference source |
Compared therapeutic range [mg/L] |
Percentage of newborns reaching the therapeutic range |
---|---|---|
Hospital therapeutic range [ |
5-10 | 38.16% |
Neofax [ |
5-12 | 71.05% |
Begg [ |
>10 | 51.39% |
van Maarseveen [ |
>8 | 68.49% |